Abbott supports patients with advanced heart failure with mechanical pumps that restore blood flow to the body, both for the short- and long-term. We design our pumps to be gentle on the blood while they are working so that patients can live longer and fuller lives.
CentriMag™ Acute Circulatory Support System is driven by the CentriMag Pump with Full MagLev™ Flow Technology. The pump includes a free-floating magnetically levitated rotor for a contact-free environment. The CentriMag System is the only acute mechanical circulatory support system approved for 30-day use*. The CentriMag System includes both pediatric and adult pump options for a wide range of patient types and sizes.
The HeartMate 3™ Left Ventricular Assist Device is indicated for short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) for advanced heart failure patients. HeartMate 3 LVAD with Full MagLev™ Flow Technology delivers unprecedented** survival and safety outcomes as demonstrated in the MOMENTUM 3 Trial at 2 years.1***
The HeartMate II™ LVAD is designed to provide short- or long-term circulatory support for advanced heart failure patients and is indicated for both destination therapy and bridge-to-transplantation in the United States. Backed by more than 10 years of data, the HeartMate II LVAD is the most widely used and extensively studied LVAD in the world, with more than 27,000 patients implanted worldwide.2,3
*PMA approval for 30-day use of CentriMag™ System components include: CentriMag™ Pump, CentriMag™ Console, CentriMag™ Motor, Mag Monitor, flow probe, and CentriMag™ Drainage Cannula and CentriMag™ Return Cannula. Optional accessories include: CentriMag™ System Cart, CentriMag™ System Transporter and Pressure Transducer. PMA approval for 30-day use of CentriMag™ System excludes: PediMag™ Blood Pump and any other pediatric components or accessories.
*Based on HeartMate 3™ LVAD highest published survival and lowest published stroke and thrombosis rates in a randomized controlled trial in the continuous-flow LVAD category of devices in the U.S.1,2-6
***HeartMate 3™ LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?